STOCK TITAN

[424B3] Medicus Pharma Ltd. Prospectus Filed Pursuant to Rule 424(b)(3)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
424B3
Rhea-AI Filing Summary

Medicus Pharma has filed a prospectus supplement (424B3) related to 1,115,500 common shares issuable upon warrant exercise. The company has appointed Andrew Smith as Chief Operating Officer, effective June 30, 2025.

Key details of the filing include:

  • Public Warrants are exercisable at $4.64 with expiration on November 15, 2029
  • Current trading prices as of June 20, 2025: Common shares at $2.49, Warrants at $0.80
  • Smith's compensation package includes $325,000 annual base salary and 100,000 stock options at $2.60 strike price, vesting quarterly over 5 years

Smith brings over 30 years of experience, previously serving as CEO of SR Asset Management and holding leadership positions at Aberdeen Asset Management. The company is listed on Nasdaq Capital Market under symbols MDCX (shares) and MDCXW (warrants) and qualifies as an emerging growth company.

Medicus Pharma ha depositato un supplemento al prospetto informativo (424B3) relativo a 1.115.500 azioni ordinarie emettibili tramite esercizio di warrant. La società ha nominato Andrew Smith come Chief Operating Officer, con decorrenza dal 30 giugno 2025.

I dettagli principali della comunicazione includono:

  • I Warrant pubblici sono esercitabili a 4,64 $ con scadenza il 15 novembre 2029
  • Prezzi di mercato al 20 giugno 2025: azioni ordinarie a 2,49 $, warrant a 0,80 $
  • Il pacchetto retributivo di Smith prevede uno stipendio base annuo di 325.000 $ e 100.000 opzioni azionarie con prezzo di esercizio di 2,60 $, con maturazione trimestrale in 5 anni

Smith vanta oltre 30 anni di esperienza, avendo ricoperto in precedenza il ruolo di CEO presso SR Asset Management e posizioni dirigenziali in Aberdeen Asset Management. La società è quotata sul Nasdaq Capital Market con i simboli MDCX (azioni) e MDCXW (warrant) e si qualifica come società in crescita emergente.

Medicus Pharma ha presentado un suplemento al prospecto (424B3) relacionado con 1.115.500 acciones comunes emitibles mediante el ejercicio de warrants. La compañía ha nombrado a Andrew Smith como Director de Operaciones, efectivo a partir del 30 de junio de 2025.

Los detalles clave de la presentación incluyen:

  • Los Warrants públicos son ejercitables a $4.64 con vencimiento el 15 de noviembre de 2029
  • Precios actuales al 20 de junio de 2025: acciones comunes a $2.49, warrants a $0.80
  • El paquete de compensación de Smith incluye un salario base anual de $325,000 y 100,000 opciones sobre acciones con precio de ejercicio de $2.60, que se consolidan trimestralmente durante 5 años

Smith aporta más de 30 años de experiencia, habiendo sido anteriormente CEO de SR Asset Management y ocupado cargos de liderazgo en Aberdeen Asset Management. La compañía cotiza en el Nasdaq Capital Market bajo los símbolos MDCX (acciones) y MDCXW (warrants) y se considera una empresa emergente en crecimiento.

Medicus Pharma는 워런트 행사로 발행 가능한 1,115,500주 보통주에 관한 증권신고서 보충서(424B3)를 제출했습니다. 회사는 2025년 6월 30일부로 Andrew Smith를 최고운영책임자(COO)로 임명했습니다.

신고서의 주요 내용은 다음과 같습니다:

  • 공개 워런트는 $4.64 행사 가격으로 2029년 11월 15일 만료
  • 2025년 6월 20일 기준 현재 거래 가격: 보통주 $2.49, 워런트 $0.80
  • Smith의 보상 패키지는 연간 기본급 $325,000 및 행사 가격 $2.60인 주식 옵션 100,000주로 구성되며, 5년 동안 분기별로 베스팅됩니다

Smith는 30년 이상의 경력을 보유하고 있으며, 이전에는 SR Asset Management의 CEO와 Aberdeen Asset Management의 주요 임원직을 역임했습니다. 회사는 나스닥 캐피털 마켓에서 MDCX(주식)와 MDCXW(워런트) 심볼로 상장되어 있으며, 신흥 성장 기업으로 분류됩니다.

Medicus Pharma a déposé un supplément au prospectus (424B3) concernant 1 115 500 actions ordinaires pouvant être émises suite à l'exercice de bons de souscription. La société a nommé Andrew Smith au poste de Directeur des Opérations, à compter du 30 juin 2025.

Les points clés du dépôt comprennent :

  • Les bons publics sont exerçables à 4,64 $ avec une date d'expiration au 15 novembre 2029
  • Prix actuels au 20 juin 2025 : actions ordinaires à 2,49 $, bons à 0,80 $
  • Le package de rémunération de Smith inclut un salaire de base annuel de 325 000 $ et 100 000 options d'achat d'actions à un prix d'exercice de 2,60 $, acquises trimestriellement sur 5 ans

Smith apporte plus de 30 ans d'expérience, ayant précédemment été PDG de SR Asset Management et occupant des postes de direction chez Aberdeen Asset Management. La société est cotée sur le Nasdaq Capital Market sous les symboles MDCX (actions) et MDCXW (bons) et est qualifiée d'entreprise en croissance émergente.

Medicus Pharma hat einen Nachtrag zum Prospekt (424B3) eingereicht, der 1.115.500 Stammaktien betrifft, die durch Ausübung von Warrants ausgegeben werden können. Das Unternehmen hat Andrew Smith mit Wirkung zum 30. Juni 2025 zum Chief Operating Officer ernannt.

Wesentliche Details der Einreichung umfassen:

  • Öffentliche Warrants sind zu einem Ausübungspreis von 4,64 $ bis zum 15. November 2029 ausübbar
  • Aktuelle Handelspreise zum 20. Juni 2025: Stammaktien bei 2,49 $, Warrants bei 0,80 $
  • Smiths Vergütungspaket beinhaltet ein jährliches Grundgehalt von 325.000 $ sowie 100.000 Aktienoptionen mit einem Ausübungspreis von 2,60 $, die vierteljährlich über 5 Jahre vesten

Smith bringt über 30 Jahre Erfahrung mit, war zuvor CEO von SR Asset Management und hatte Führungspositionen bei Aberdeen Asset Management inne. Das Unternehmen ist an der Nasdaq Capital Market unter den Symbolen MDCX (Aktien) und MDCXW (Warrants) gelistet und gilt als wachsendes Jungunternehmen.

Positive
  • Appointment of highly experienced COO Andrew Smith with over 30 years of leadership experience in asset management and financial operations
  • New COO brings significant C-suite experience, including roles as Chairman/CEO of SR Asset Management and COO of Aberdeen Asset Management's Americas division
  • COO compensation package includes performance-aligned equity with 100,000 stock options vesting over 5 years, promoting long-term commitment
Negative
  • Current stock price of $2.49 is significantly below the warrant exercise price of $4.64, indicating market skepticism about near-term growth prospects
  • Warrants trading at $0.80 suggest market doubts about the company reaching the $4.64 exercise price before November 2029 expiration

Medicus Pharma ha depositato un supplemento al prospetto informativo (424B3) relativo a 1.115.500 azioni ordinarie emettibili tramite esercizio di warrant. La società ha nominato Andrew Smith come Chief Operating Officer, con decorrenza dal 30 giugno 2025.

I dettagli principali della comunicazione includono:

  • I Warrant pubblici sono esercitabili a 4,64 $ con scadenza il 15 novembre 2029
  • Prezzi di mercato al 20 giugno 2025: azioni ordinarie a 2,49 $, warrant a 0,80 $
  • Il pacchetto retributivo di Smith prevede uno stipendio base annuo di 325.000 $ e 100.000 opzioni azionarie con prezzo di esercizio di 2,60 $, con maturazione trimestrale in 5 anni

Smith vanta oltre 30 anni di esperienza, avendo ricoperto in precedenza il ruolo di CEO presso SR Asset Management e posizioni dirigenziali in Aberdeen Asset Management. La società è quotata sul Nasdaq Capital Market con i simboli MDCX (azioni) e MDCXW (warrant) e si qualifica come società in crescita emergente.

Medicus Pharma ha presentado un suplemento al prospecto (424B3) relacionado con 1.115.500 acciones comunes emitibles mediante el ejercicio de warrants. La compañía ha nombrado a Andrew Smith como Director de Operaciones, efectivo a partir del 30 de junio de 2025.

Los detalles clave de la presentación incluyen:

  • Los Warrants públicos son ejercitables a $4.64 con vencimiento el 15 de noviembre de 2029
  • Precios actuales al 20 de junio de 2025: acciones comunes a $2.49, warrants a $0.80
  • El paquete de compensación de Smith incluye un salario base anual de $325,000 y 100,000 opciones sobre acciones con precio de ejercicio de $2.60, que se consolidan trimestralmente durante 5 años

Smith aporta más de 30 años de experiencia, habiendo sido anteriormente CEO de SR Asset Management y ocupado cargos de liderazgo en Aberdeen Asset Management. La compañía cotiza en el Nasdaq Capital Market bajo los símbolos MDCX (acciones) y MDCXW (warrants) y se considera una empresa emergente en crecimiento.

Medicus Pharma는 워런트 행사로 발행 가능한 1,115,500주 보통주에 관한 증권신고서 보충서(424B3)를 제출했습니다. 회사는 2025년 6월 30일부로 Andrew Smith를 최고운영책임자(COO)로 임명했습니다.

신고서의 주요 내용은 다음과 같습니다:

  • 공개 워런트는 $4.64 행사 가격으로 2029년 11월 15일 만료
  • 2025년 6월 20일 기준 현재 거래 가격: 보통주 $2.49, 워런트 $0.80
  • Smith의 보상 패키지는 연간 기본급 $325,000 및 행사 가격 $2.60인 주식 옵션 100,000주로 구성되며, 5년 동안 분기별로 베스팅됩니다

Smith는 30년 이상의 경력을 보유하고 있으며, 이전에는 SR Asset Management의 CEO와 Aberdeen Asset Management의 주요 임원직을 역임했습니다. 회사는 나스닥 캐피털 마켓에서 MDCX(주식)와 MDCXW(워런트) 심볼로 상장되어 있으며, 신흥 성장 기업으로 분류됩니다.

Medicus Pharma a déposé un supplément au prospectus (424B3) concernant 1 115 500 actions ordinaires pouvant être émises suite à l'exercice de bons de souscription. La société a nommé Andrew Smith au poste de Directeur des Opérations, à compter du 30 juin 2025.

Les points clés du dépôt comprennent :

  • Les bons publics sont exerçables à 4,64 $ avec une date d'expiration au 15 novembre 2029
  • Prix actuels au 20 juin 2025 : actions ordinaires à 2,49 $, bons à 0,80 $
  • Le package de rémunération de Smith inclut un salaire de base annuel de 325 000 $ et 100 000 options d'achat d'actions à un prix d'exercice de 2,60 $, acquises trimestriellement sur 5 ans

Smith apporte plus de 30 ans d'expérience, ayant précédemment été PDG de SR Asset Management et occupant des postes de direction chez Aberdeen Asset Management. La société est cotée sur le Nasdaq Capital Market sous les symboles MDCX (actions) et MDCXW (bons) et est qualifiée d'entreprise en croissance émergente.

Medicus Pharma hat einen Nachtrag zum Prospekt (424B3) eingereicht, der 1.115.500 Stammaktien betrifft, die durch Ausübung von Warrants ausgegeben werden können. Das Unternehmen hat Andrew Smith mit Wirkung zum 30. Juni 2025 zum Chief Operating Officer ernannt.

Wesentliche Details der Einreichung umfassen:

  • Öffentliche Warrants sind zu einem Ausübungspreis von 4,64 $ bis zum 15. November 2029 ausübbar
  • Aktuelle Handelspreise zum 20. Juni 2025: Stammaktien bei 2,49 $, Warrants bei 0,80 $
  • Smiths Vergütungspaket beinhaltet ein jährliches Grundgehalt von 325.000 $ sowie 100.000 Aktienoptionen mit einem Ausübungspreis von 2,60 $, die vierteljährlich über 5 Jahre vesten

Smith bringt über 30 Jahre Erfahrung mit, war zuvor CEO von SR Asset Management und hatte Führungspositionen bei Aberdeen Asset Management inne. Das Unternehmen ist an der Nasdaq Capital Market unter den Symbolen MDCX (Aktien) und MDCXW (Warrants) gelistet und gilt als wachsendes Jungunternehmen.


Filed Pursuant to Rule 424(b)(3)

Registration No. 333-279771

PROSPECTUS SUPPLEMENT NO. 7

(to prospectus dated April 10, 2025)

Medicus Pharma Ltd.

1,115,500 Common Shares Issuable upon the Exercise of Warrants


This prospectus supplement amends and supplements the prospectus dated effective April 10, 2025, as supplemented or amended from time to time (the "Prospectus"), which forms a part of our Registration Statement on Form S-1 (Registration Statement No. 333-279771). This prospectus supplement is being filed to update and supplement the information included or incorporated by reference in the Prospectus with the information contained in our Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 23, 2025 (the "Form 8-K"). Accordingly, we have attached the Form 8-K to this prospectus supplement.

This prospectus supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.

Our common shares and warrants, with an exercise price of $4.64 and expiration date of November 15, 2029 (the "Public Warrants"), are listed on The Nasdaq Capital Market ("Nasdaq") under the symbols "MDCX" and "MDCXW," respectively. On June 20, 2025, the last reported sales prices of the common shares and Public Warrants were $2.49 and $0.80, respectively.

We are an "emerging growth company" under applicable Securities and Exchange Commission rules and are eligible for reduced public company disclosure requirements.

Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described under the heading "Risk Factors" beginning on page 10 of the Prospectus, and under similar headings in any amendment or supplements to the Prospectus.

None of the Securities and Exchange Commission, any state securities commission or the securities commission of any Canadian province or territory has approved or disapproved of the securities offered by this prospectus supplement or the Prospectus or determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement is June 23, 2025.



UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

___________________________

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 23, 2025

MEDICUS PHARMA LTD.
(Exact name of registrant as specified in its charter)

Ontario 001-42408 98-1778211
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)

300 Conshohocken State Road, Suite 200
Conshohocken, Pennsylvania, United States 19428
(Address of principal executive offices) (ZIP Code)

Registrant's telephone number, including area code: (610) 540-7515

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class   Trading Symbols   Name of each exchange on which
        registered
Common shares, no par value   MDCX   NASDAQ Capital Market
Warrants, each exercisable for one   MDCXW   NASDAQ Capital Market
common share at an exercise price of        
$4.64 per share        

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b -2 of this chapter).

Emerging growth company ☑

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 23, 2025, Medicus Pharma Ltd. (the "Company") announced the appointment of Andrew Smith, age 57, to serve as the Company's Chief Operating Officer ("COO"). Mr. Smith first joined the Company as a consultant on May 27, 2025 and will transition to his new role as COO on or about June 30, 2025.

Mr. Smith joins the Company with over three decades experience and is an accomplished C-suite professional with a successful track record as a leader in asset management and financial operations. Most recently, Mr. Smith served as a Consultant and Business Advisor to Connor Capital SB, LLC ("Connor Capital") from April 2024 to September 2024. Prior to joining Connor Capital, Mr. Smith served as the Chairman and Chief Executive Officer of SR Asset Management, LLC ("SRAM") from January 2017 until its sale in June 2024. Before joining SRAM, Mr. Smith held various leadership positions at Aberdeen Asset Management Inc. ("Aberdeen"), including as the Co-Head of Americas and Chief Operating Officer from 2014 to 2016, as Aberdeen's Chief Financial and Chief Operating Officer and as the Chief Compliance Officer for Aberdeen's North American Closed End Funds from 2005 until 2013, and as the Vice President of Finance & Administration from 2001 until 2004. He currently sits on the board of HazelTree Fund Services and is an advisor to Code Registry. Mr. Smith holds an Executive MBA from INSEAD in Fountainebleau and received an HND in Accounting from Glasgow College of Commerce, Scotland.

The Company entered into an agreement with Mr. Smith to memorialize his employment (the "Employment Agreement"). Pursuant to the terms of the Employment Agreement, Mr. Smith will commence employment as COO on or about June 30, 2025. In this role, Mr. Smith will receive an annual base salary of $325,000. Mr. Smith will also receive a grant of 100,000 stock options covering shares of the Company common stock with a strike price of $2.60 per share, vesting quarterly over the next five years, subject to Mr. Smith's continued service to the Company through each vesting date.

There are no family relationships between Mr. Smith and any director or executive officer of the Company pursuant to Item 401(d) of Regulation S-K and the Company has not entered into any transactions with Mr. Smith that are reportable pursuant to Item 404(a) of Regulation S-K. Except as described above, there are no arrangements or understandings between Mr. Smith and any other persons pursuant to which he will be appointed as an executive officer of the Company.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

MEDICUS PHARMA LTD.

By: /s/ Raza Bokhari
Name: Dr. Raza Bokhari
Title: Executive Chairman and Chief Executive Officer

Dated: June 23, 2025


FAQ

Who is MDCX's new Chief Operating Officer and when does he start?

Andrew Smith, age 57, has been appointed as MDCX's new Chief Operating Officer, starting on June 30, 2025. He brings over three decades of experience and previously served as Chairman and CEO of SR Asset Management, LLC and held various leadership positions at Aberdeen Asset Management Inc.

What is the compensation package for MDCX's new COO Andrew Smith?

Andrew Smith's compensation package includes an annual base salary of $325,000 and a grant of 100,000 stock options with a strike price of $2.60 per share. The stock options vest quarterly over five years, contingent on his continued service with the company.

What is the current trading price of MDCX stock and warrants?

As of June 20, 2025, MDCX common shares were trading at $2.49 on the Nasdaq Capital Market, while the Public Warrants (MDCXW) were trading at $0.80. The warrants have an exercise price of $4.64 and expire on November 15, 2029.

What is Andrew Smith's professional background before joining MDCX?

Prior to joining MDCX, Smith served as a Consultant at Connor Capital SB, LLC (April-September 2024), Chairman and CEO of SR Asset Management until its sale in June 2024, and held various leadership roles at Aberdeen Asset Management Inc. including Co-Head of Americas and COO (2014-2016). He holds an Executive MBA from INSEAD and an HND in Accounting from Glasgow College of Commerce.

How many common shares is MDCX registering in this prospectus supplement?

MDCX is registering 1,115,500 common shares that are issuable upon the exercise of warrants, as detailed in Prospectus Supplement No. 7 to the prospectus dated April 10, 2025.
Medicus Pharma Ltd

NASDAQ:MDCX

MDCX Rankings

MDCX Latest News

MDCX Latest SEC Filings

MDCX Stock Data

39.04M
8.72M
Pharmaceutical Preparations
W. CONSHOHOCKEN